Edvince

Edvince AB granted EU Orphan Medicinal Product Designation for EDV2209 in treatment of non-traumatic subarachnoid hemorrhage

Tue, Nov 21, 2017 10:45 CET

On November 8th Edvince AB received a positive decision from the European Commission, granting the EDV2209 drug Orphan Medicinal Product Designation for treatment of non-traumatic subarachnoid hemorrhage. Edvince AB is a Life Science R&D company that develops a new treatment to minimize brain damage in patients that has suffered a bleeding in the brain – subarachnoid hemorrhage – caused by brain aneurysm.Orphan medicinal product designation can be granted by the European Commission for diseases with a prevalence of less than 5 individuals per 10,000. Orphan medicinal product designation

Edvince AB was granted FDA Orphan-Drug Designation for EDV2209 in treatment of subarachnoid hemorrhage

Thu, Aug 10, 2017 10:19 CET

Edvince AB, a biotech company that is developing a new treatment concept to minimize brain damage subsequent to cerebral ischemia, received a positive response from the US Food and Drug Administration (FDA) on august 3rd, granting the EDV2209 drug orphan-drug designation for treatment of subarachnoid hemorrhage.Orphan-drug designation can in the USA be granted for treatments targeting diseases with less than 200,000 patients yearly. Orphan-drug designation status for a drug is valuable, and comes with many developmental and market benefits. For example, development cost tax incentives and

Share

Edvince AB granted EU Orphan Medicinal Product Designation for EDV2209 in treatment of non-traumatic subarachnoid hemorrhage

Edvince AB was granted FDA Orphan-Drug Designation for EDV2209 in treatment of subarachnoid hemorrhage